Cited 281 times in
Osimertinib Plus Savolitinib in Patients With EGFR Mutation-Positive, MET-amplified, Non-Small-Cell Lung Cancer After Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results From a Multicentre, Open-Label, Phase 1b Study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.